# Buyers with power: payers, GPOs, and hospital systems as gatekeepers
A cardiologist writes a prescription for a new anticoagulant. She believes it is the best drug for her patient. But whether that patient can actually get it, and at what copay, was decided months earlier in a contract negotiation she never saw, between a drug maker and a pharmacy benefit manager she has never met. That gap between the person who prescribes and the person who decides what gets bought is the single most important power dynamic in this sector.
In most industries, the person who chooses the product pays for it. Healthcare breaks this link three ways:
Because the payer holds the money, the payer holds the power. And in the US especially, a set of intermediaries has grown up between drug makers and patients whose entire business is controlling access. Understanding these gatekeepers is understanding where margin goes.
A PBM is a company that administers prescription drug benefits on behalf of insurers, employers, and government plans. It decides which drugs are covered, negotiates prices with manufacturers, and pays pharmacies.
The US PBM market is extraordinarily concentrated. Three players,
Their main lever is the formulary: the list of covered drugs, sorted into tiers. Tier 1 is cheap generics with low copays. Higher tiers cost the patient more, or require prior authorization (the doctor must justify the prescription before it is covered) or step therapy (the patient must fail on a cheaper drug first).
Here is the mechanism that confuses most newcomers. A drug maker does not simply set a price. It sets a high list price, then pays the PBM a rebate (a retroactive discount) to win favorable formulary placement.
A simplified worked example (illustrative numbers, not a real drug):
The manufacturer gave up $400 of margin to avoid being excluded or buried on Tier 4. If a competitor offers a 50 percent rebate, the PBM may switch, and the first drug's volume collapses overnight. This is why formulary exclusion is a genuine existential threat: a drug can be clinically excellent and still fail commercially because it lost a rebate auction.
The controversy: part of that rebate is retained by the PBM rather than passed to the patient, whose copay is often calculated off the high list price. Regulators have circled this for years. For a clear neutral primer, see the KFF explainer on PBMs.
The line between insurer, PBM, and provider has blurred. UnitedHealth Group owns OptumRx (PBM), Optum Health (clinics and physicians), and UnitedHealthcare (the insurer). Cigna owns Express Scripts. CVS Health owns Caremark and Aetna (an insurer).
This vertical integration matters for power because it internalizes the whole chain. When one company owns the insurer, the PBM, and increasingly the clinics, it can steer patients, control formularies, and capture margin at multiple points. For a biotech selling a drug, you are no longer negotiating with a single buyer. You are negotiating with a machine that controls coverage, pharmacy, and care delivery at once.
Pharmaceuticals flow through PBMs. Physical products (surgical devices, implants, sutures, imaging equipment, IV bags) flow through a different gatekeeper: the Group Purchasing Organization (GPO).
A GPO aggregates the buying power of many hospitals to negotiate lower prices from suppliers. Instead of one hospital negotiating for 200 hip implants, a GPO negotiates for 200,000. The big US GPOs, commonly cited as Vizient, Premier, and HealthTrust, together are estimated to touch the large majority of US hospital purchasing (estimate).
For a medtech company, the critical question is: are you on the GPO contract? If a GPO has an exclusive or preferred agreement with your competitor, hospitals in that GPO face financial penalties for buying from you, even if a surgeon prefers your device.
GPOs are funded largely through administrative fees (often around 3 percent, an estimate that varies), paid by the supplier as a percentage of sales routed through the contract. So the supplier pays for the privilege of access, similar to the PBM rebate logic.
This creates a hard barrier for challengers. A startup with a superior catheter cannot simply win on merit at the bedside. It must win a contract slot, and incumbents fight to keep those slots locked and exclusive.
Behind the GPO sits the hospital system itself, and these have consolidated aggressively. Large integrated delivery networks (HCA Healthcare, CommonSpirit Health, and academic systems) buy at scale and increasingly employ the physicians directly.
This is the second decoupling of prescriber from buyer. When a surgeon is a hospital employee, the hospital's value analysis committee (a group that reviews the cost and clinical evidence of new products) can veto a device the surgeon wants because it is not on contract or not cost justified. Physician preference still matters for high-stakes implants, but the committee holds the purse.
Vérification des acquis
1. The lesson argues that the most important power dynamic in healthcare is the gap between the prescriber and the decision-maker on purchasing. What underlying feature of healthcare makes this gap possible?
2. Why does the lesson state that 'because the payer holds the money, the payer holds the power'?
3. A PBM places a new branded drug on a high formulary tier and requires prior authorization. From the manufacturer's perspective, what is the primary strategic consequence?
4. Select ALL correct answers about why the US PBM market's structure gives these intermediaries significant leverage over drug makers.
Sélectionnez toutes les réponses correctes.
5. Select ALL correct answers describing the function of a formulary as a gatekeeping tool.
Sélectionnez toutes les réponses correctes.
Put the chain together and the pattern is clear. Value is created by innovators (biotech, medtech), but margin is captured disproportionately by the intermediaries who control access.
How does a new entrant break through? Three real strategies:
1. Clinical differentiation so strong that exclusion is untenable. If your drug is the only treatment for a disease, the PBM cannot exclude it without an outcry. Rare disease and oncology innovators use this.
2. Health economic evidence. Demonstrate that your device reduces total cost (fewer readmissions, shorter stays). This appeals to value analysis committees and value based contracts.
3. Going direct. Some manufacturers now bypass PBMs. Mark Cuban Cost Plus Drugs, launched 2022, sells generics direct with a transparent markup, sidestepping the rebate system. Eli Lilly and others have launched direct to patient channels for certain drugs. These are early challenges to the intermediary model, not yet a replacement.
In Europe, the dominant buyer is usually the state. Bodies like the UK's NICE (National Institute for Health and Care Excellence) conduct health technology assessment (evaluating whether a product delivers enough benefit for its cost) before national reimbursement. Germany's G-BA and IQWiG play a similar role.
The power dynamic differs: instead of fragmented private PBMs and GPOs, a single national payer negotiates. This gives European buyers enormous leverage on price, which is why list prices for the same drug are often lower in Europe than the US. But it also means one negative assessment can shut a company out of an entire country. The gatekeeper is centralized, not commercialized.